Table 1 Characteristic of the patients
From: Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
Disease Response | ||
|---|---|---|
Complete Remission CR | Treatment Failure TF | |
Patient Characteristics | Number (%) | Number (%) |
Total patients enrolled | 16 | 10 |
Female | 6 (37%) | 8 (80%) |
Median Age (years, range) | 61 (35–75) | 62 (38–74) |
Disease State on enrollment* | ||
Untreated AML | 12 (80%) | 2 (22%) |
Relapse/refractory AML | 3 (20%) | 7 (78%) |
Initial AML diagnosis* | ||
De Novo AML | 8 (53%) | 5 (55%) |
Secondary AML after MDS | 7 (47%) | 4 (45%) |
Acquired Mutation Status* | ||
FLT3 | 3 (20%) NMP1 mutated | 2 (22%) NMP1 mutated |
CEPBA | 1 (6%) | 2 (22%) |
NMP1 | 5 (34%) | 1 (11%) |
Blast (CD34+) | ||
Median | 9.90% | 48.90% |
Range | 4.5–89.7 | 7.9–76.6 |